TriangleVS-7375 (NCT07659795)
VS-7375 trial for Colorectal Cancer (NCT07659795). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic KRAS G12D-mutated colorectal cancer, either starting treatment or progressing after chemotherapy with prior disease control. Previous direct RAS inhibitors or other common RAS mutations exclude participation.
The idea: oral VS-7375 targets active and inactive KRAS G12D. Previously treated groups test it alone or with cetuximab or panitumumab. The first-line group combines it with cetuximab and mFOLFOX chemotherapy. Researchers assess response and safety; treatment depends on the study group.
This phase 2 study plans 150 patients. Verastem sponsors 23 recruiting US locations.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.